Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen ...

Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor T Cells for Diffuse Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma ... Progenitor ...

The T cells will be modified with a protein called chimeric antigen receptor (CAR), which will give the newly created CAR-T cells the ability to identify and ...

Phase I Trial of GD2.CART Cells Augmented With Constitutive ...

One patient with DMG demonstrating partial response on dose level 1 re-enrolled onto dose level 2. CART, chimeric antigen receptor; DL, dose ...

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG ...

H3K27Mmutant testing will occur as part of standard of care prior to enrollment. Official Title. Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen ...

Safety and biological outcomes following a phase 1 trial of GD2 ...

Autologous GD2-specific chimeric antigen receptor (CAR) T cell products manufactured using the original protocol (pink symbols) or modified ...

GD2CART for the Treatment of H3K27M Mutated Diffuse Intrinsic ...

This phase I trial investigates the side effects and best dose of autologous GD2 chimeric antigen receptor (CAR) T cells (GD2CART) and how well it works in ...

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

... antigen. Few early-phase clinical trials of GD2-targeted CAR T cells have shown that the approach is feasible, and few objective responses ...

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

Background: Immunotherapy with chimeric antigen receptor (CAR)- ... Methods: In an academic, phase 1-2 clinical trial, we enrolled ...

Autologous anti-GD2 CAR T cells efficiently target primary human ...

Autologous chimeric antigen receptor (CAR) T cell therapy has been changing the therapeutic landscape of hematological malignancies, and ...

Clinical Trials Using Autologous Anti-GD2-CAR-BBz-iCasp9 ...

This phase I trial investigates the side effects and best dose of autologous GD2 chimeric antigen receptor (CAR) T cells (GD2CART) and how well it works in ...

Abstract CT118: CARPETS: A Phase I study of the safety and ...

Abstract CT118: CARPETS: A Phase I study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor- ...

KARPOS - A Phase 1, Single-Centre, Non-randomised ... - LARVOL

A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood ...

GD2 targeting CAR T cells for neuroblastoma - ScienceDirect.com

... phase III clinical trial [1]. The role of ASCT (both single and tandem) in ... Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen ...

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

... GD2-directed chimeric antigen receptor (CAR) T cells2, providing the rationale for a first-in-human phase I clinical trial (NCT04196413) ...

Clinical Trials - Adult and Pediatric Trials - UNC Lineberger

Relapsed/Refractory Glioblastoma. LCCC2059-ATL (NCT05366179): Phase 1 Study of Autologous ... chimeric antigen receptor cells against the GD2 antigen (iC9-GD2.

Safety and antitumor activity of GD2-Specific 4SCAR-T cells in ...

This study aimed to validate whether infusion of GD2-specific fourth-generation safety-designed chimeric antigen receptor (4SCAR)-T cells is ...

Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen ...

Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T ... Study Type: Interventional. Study Phase: Phase 1. Connect me to this trial. SUMMARY.

Abstract CT145: A Cancer Research UK phase I trial of anti-GD2 ...

Here, we report the preliminary results of a Phase I clinical study of GD2 ... A Cancer Research UK phase I trial of anti-GD2 chimeric antigen ...

GD2-CAR T-Cell Therapy Yields Clinical Benefit in Glioma - CGTLive®

... GD2-chimeric antigen receptor (CAR) T-cell therapy. 1. These ... The phase 1, dose escalation trial has enrolled 13 participants, 11 ...

Cancer and Hematology Center GD2 Specific CAR and Interleukin ...

In a previous clinical trial, investigators made artificial genes called a chimeric antigen receptors (CAR), from an antibody called 14g2a that recognizes GD2 ...